The Clarification from Amgen on Wednesday, November 13th, stated that there is no connection between its experimental weight loss drug and changes in bone density. The results of the Phase I study do not indicate any bone safety issues or alter our confidence in the prospects of MariTide. Previously, analysts at Cantor Fitzgerald stated that their review of early data on MariTide, a subsidiary of Amgen, showed that the drug led to a decrease in bone density, causing the company's stock price to drop by 7% on Tuesday, wiping out over $12 billion in market cap. However, at least four analysts have expressed that these concerns have been exaggerated, especially considering that the company is conducting a mid-term study and planning to invest in a larger late-stage trial.